The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at Almirall, and Esteve’s European Expansion.
Weapons “made in Spain” in the war against Covid-19 (La Razón – Spanish)
https://www.larazon.es/salud/20201214/iecgoyhkpfeifhlfgpracvgtci.html
Spain takes center stage in the fight against SARS-CoV-2 with the national production of syringes and vaccines, masks or tests against the virus.
Grifols enters Egypt with a plan of 250 million (La Vanguardia – Spanish)
https://www.lavanguardia.com/economia/20201125/49681209026/grifols-egipto-acuerdo-mpresarial.html
Grifols has signed an agreement with the Egyptian state company National Service Projects Organization (NSPO) to jointly invest around 250 million euros (300 million dollars) with which they will open a network of 20 plasma centers and fractionation plants in the country and protein purification, as announced yesterday to the CNMV.
Almirall: The Third Generation of the Gallardos Ready to Take Over (La Razón – Spanish)
https://www.larazon.es/economia/20201122/vbfvsxkotzcfjlu6rwknod35wu.html
Carlos Gallardo, son of the current president, has been appointed vice president of the Board of Directors of the pharmaceutical company
Ferrer accesses a loan of 50 million from the EIB (El Periódico – Spanish)
https://www.elperiodico.com/es/economia/20201214/ferrer-accede-prestamo-50-millones-11386015
The pharmaceutical company Ferrer has signed a loan of 50 million euros with the European Investment Bank (EIB) in order to promote innovation projects in the areas of pulmonology and neurology.
Esteve, determined to make purchases and expand its European presence (El País – Spanish)
https://cincodias.elpais.com/cincodias/2020/11/15/companias/1605456330_423881.html
The group’s chief executive targets Italy, Scandinavia and the Eastern countries. The pharmaceutical company Esteve is “clearly” determined to face acquisitions that fit with its business strategy despite the COVID-19 crisis and to expand its presence in Europe.
